Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years

TANDEM DIABETES CARE INC

On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
The Development Agreement covers integration of Tandem's Sigi insulin pump with Dexcom's G7 CGM.
Both agreements extend the term to five years and amend definitions and commercial terms.
The Commercialization Agreement addresses the sale and support of the integrated systems.
Original agreements were signed November 2020; new deals update device scope and conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.